---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-026070"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:50:14.020130+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics reports Q4 net loss of $90.4M; cash $850.7M, clinical milestones reaffirmed

## Summary
- Net loss per share $1.09 in Q4 2024 vs net income of $1.77 in Q4 2023; full-year net loss $4.58 per share vs $1.72 in 2023.
- Cash, equivalents and marketable securities $850.7M at Dec 31, 2024, expected to fund operations into 2027.
- Adult enrollment target achieved in BEACON trial of BEAM-101; updated data and 30 patients dosed expected by mid-2025.
- Initial data from BEAM-302 Phase 1/2 in alpha-1 antitrypsin deficiency expected in H1 2025; BEAM-301 dosing to start early 2025.
- Appointed Sravan Emany as CFO; Chirfi Guindo to board; IND-enabling studies for ESCAPE conditioning ongoing.

## SEC filing metadata
- accession: 0000950170-25-026070
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017025026070/0000950170-25-026070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017025026070/beam-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-026070
- JSON: https://secwatch.observer/filing/0000950170-25-026070.json
- Plain text: https://secwatch.observer/filing/0000950170-25-026070.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.